Clinical Trials on Acquired Immunodeficiency Syndrome in United States

Total 14406 results

Argus Pharmaceuticals

Completed

Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)

HIV Infections

United States
EMD Serono

Completed

Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

United States, Canada
St. Hope Foundation
GlaxoSmithKline

Completed

Switching Undetectables to Selzentry (SUDS)

Human Immunodeficiency Virus | AIDS

United States
Seagen Inc.

Withdrawn

A Safety Study of Brentuximab Vedotin in Participants With HIV

Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Drug-drug Interaction (DDI) Rifabutin

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

GSK706769 Repeat Dose Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Bristol-Myers Squibb

Completed

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat (Atazanavir)

Human Immunodeficiency Virus Type 1 (HIV-1)

United States
Bristol-Myers Squibb
Medarex

Completed

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV)

United States
University of Miami
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Evaluating an Exercise Program to Reduce Cardiovascular Risk Factors in Children Infected With HIV

Cardiovascular Diseases | Acquired Immunodeficiency Syndrome | HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

White Blood Cell Infusions to Treat HIV Infection

Acquired Immunodeficiency Syndrome | HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Interleukin-2 Therapy for HIV Infection - Supplemental Procedures

Acquired Immunodeficiency Syndrome | HIV Infection

United States
University of California, San Francisco

Completed

Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) (AP6142)

Human Immunodeficiency Virus | Drug Interactions

United States
Gilead Sciences

Terminated

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, Thailand, Spain, Uganda, South Africa, Italy
VA Office of Research and Development

Completed

Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH) (MESH)

Smoking | Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

GSK1349572 Drug Interaction Study With Efavirenz

Infections, Human Immunodeficiency Virus and Herpesviridae

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Infections, Human Immunodeficiency Virus and Herpesviridae

United States
ViiV Healthcare
Glaxosmithkline/Quintiles

Completed

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between Dolutegravir and Prednisone

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

DDI Study of Etravirine and GSK1265744

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
University of Pennsylvania
National Institute on Minority Health and Health Disparities (NIMHD)

Completed

Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men (STAND)

Human Immunodeficiency Virus (HIV) | Sexually Transmitted Disease (STD)

United States
University of North Carolina, Chapel Hill

Completed

Managerial Database II

Acquired Immunodeficiency Syndrome

United States
Gilead Sciences

Completed

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States
Bristol-Myers Squibb

Completed

A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)

HIV Infections

United States
American Gene Technologies International Inc.

Enrolling by invitation

An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy

HIV

United States
Bristol-Myers Squibb

Completed

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

HIV Infections | Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Netherlands
Columbia University

Completed

mVIP (Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV) (mVIP)

HIV (Human Immunodeficiency Virus)

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

GSK1349572 Relative Bioavailability Study

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Terminated

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Terminated

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Withdrawn

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

Infections, Human Immunodeficiency Virus and Herpesviridae

United States
GlaxoSmithKline

Completed

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

Infection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and Herpesviridae

United States
Fred Hutchinson Cancer Center
University of Washington

Completed

MMF for HIV Reservoir Reduction

Human Immunodeficiency Virus I Infection

United States
Auritec Pharmaceuticals
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women

Human Immunodeficiency Virus (HIV) Prophylaxis

United States

Clinical Trials on Acquired Immunodeficiency Syndrome in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations